KR20230038728A - 항-알파-4-베타-7 항체 - Google Patents

항-알파-4-베타-7 항체 Download PDF

Info

Publication number
KR20230038728A
KR20230038728A KR1020237004136A KR20237004136A KR20230038728A KR 20230038728 A KR20230038728 A KR 20230038728A KR 1020237004136 A KR1020237004136 A KR 1020237004136A KR 20237004136 A KR20237004136 A KR 20237004136A KR 20230038728 A KR20230038728 A KR 20230038728A
Authority
KR
South Korea
Prior art keywords
ser
val
leu
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237004136A
Other languages
English (en)
Korean (ko)
Inventor
징 민
테레사 응 (이옥-찬)
로렌조 베나투일
재클린 빅스비
타티아나 데크티아르
펑 둥
주니어 악셀 에르난데스
프리티 크리쉬난
량쥔 루
페데리코 멘사
르네 밀러
가우탐 사후
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Publication of KR20230038728A publication Critical patent/KR20230038728A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
KR1020237004136A 2020-07-16 2021-07-16 항-알파-4-베타-7 항체 Pending KR20230038728A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052933P 2020-07-16 2020-07-16
US63/052,933 2020-07-16
PCT/US2021/070898 WO2022016198A1 (en) 2020-07-16 2021-07-16 Anti-αlpha-4-βeta-7 antibodies

Publications (1)

Publication Number Publication Date
KR20230038728A true KR20230038728A (ko) 2023-03-21

Family

ID=77338969

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004136A Pending KR20230038728A (ko) 2020-07-16 2021-07-16 항-알파-4-베타-7 항체

Country Status (15)

Country Link
US (2) US11639390B2 (enExample)
EP (1) EP4182349A1 (enExample)
JP (2) JP7408008B2 (enExample)
KR (1) KR20230038728A (enExample)
CN (1) CN115867352A (enExample)
AR (1) AR122983A1 (enExample)
AU (1) AU2021307468A1 (enExample)
CA (1) CA3188739A1 (enExample)
CO (1) CO2023001066A2 (enExample)
IL (1) IL299767A (enExample)
MX (1) MX2023000732A (enExample)
TW (1) TWI889871B (enExample)
UY (1) UY39327A (enExample)
WO (1) WO2022016198A1 (enExample)
ZA (1) ZA202300222B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2025038861A1 (en) * 2023-08-15 2025-02-20 Abbvie Inc. Methods of treating human immunodeficiency virus (hiv) disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AP2015008338A0 (en) * 2012-09-26 2015-04-30 Kflp Biotech Llc Compounds for the treatment and prevention of retroviral infections
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Also Published As

Publication number Publication date
MX2023000732A (es) 2023-02-13
CA3188739A1 (en) 2022-01-20
JP7765447B2 (ja) 2025-11-06
UY39327A (es) 2022-02-25
CN115867352A (zh) 2023-03-28
BR112023000718A2 (pt) 2023-02-07
EP4182349A1 (en) 2023-05-24
ZA202300222B (en) 2023-09-27
CO2023001066A2 (es) 2023-02-06
JP7408008B2 (ja) 2024-01-04
US20220017624A1 (en) 2022-01-20
US11639390B2 (en) 2023-05-02
TWI889871B (zh) 2025-07-11
TW202216781A (zh) 2022-05-01
AU2021307468A1 (en) 2023-02-02
JP2024037932A (ja) 2024-03-19
AR122983A1 (es) 2022-10-19
IL299767A (en) 2023-03-01
WO2022016198A1 (en) 2022-01-20
US20260062488A1 (en) 2026-03-05
JP2023535556A (ja) 2023-08-18

Similar Documents

Publication Publication Date Title
JP7610302B2 (ja) Ｃｃｒ８抗体及びその用途
AU2019370339B2 (en) Bispecific antibody and use thereof
JP2023105024A (ja) 抗体およびその使用方法
JP6867955B2 (ja) 抗ｏｘ４０抗体及びその使用方法
KR102341926B1 (ko) 항-ox40 항체 및 이의 용도
CN102459343B (zh) 用于治疗hiv的抗cxcr4抗体
US20260062488A1 (en) Anti-alpha-4-beta-7 antibodies
JP2022502076A (ja) 抗ｔｎｆｒ２抗体およびその使用
KR102369118B1 (ko) 인간화 항-basigin 항체 및 이의 용도
US12227580B2 (en) Antigen binding molecules that bind LIGHT
GB2566389B (en) Antigen binding molecules that bind light
TW202112826A (zh) 抗tigit抗體及使用方法
CA3196493A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
BR122024013054A2 (pt) Anticorpo monoclonal humano anti-alfa-4--beta-7
BR112023000718B1 (pt) Anticorpo monoclonal anti-alfa-4-beta-7 humano
CN116685603A (zh) B和t淋巴细胞衰减因子（btla）调节剂及其使用方法
EA048894B1 (ru) Антитела к l1cam и их применение
HK1165813B (en) Anti cxcr4 antibodies for the treatment of hiv
HK1182725A (en) Antibodies for the treatment of hiv

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240712

Comment text: Request for Examination of Application